Evolution of First-Line Immune Checkpoint Inhibition in Advanced or Metastatic Solid Tumors : Episode 2
A Historical Perspective on First-Line Treatment of NSCLC and Recent Advances in Immunotherapy
In the first installment of this series, Joshua Sabari, MD, provides an overview on the use of chemotherapy for first-line treatment of NSCLC, and discusses how the more recent availability of PD-1/PD-L1– and CTLA-4–targeted immunotherapy is changing the field.
EP: 1.Overview of Immune Checkpoint Inhibitors in NSCLC
Now Viewing
EP: 2.A Historical Perspective on First-Line Treatment of NSCLC and Recent Advances in Immunotherapy
EP: 3.First-Line Treatment Paradigm of NSCLC and the Advent of Immunotherapy
EP: 4.First-Line Treatment of mNSCLC with Combination Immunotherapy plus Chemotherapy and Key Data Updates from POSEIDON
EP: 5.First-Line Combination Immunotherapy plus Chemotherapy in mNSCLC
EP: 6.Clinical Implications of Recent Advancements in Immunotherapy for NSCLC
EP: 7.Key Updates in the Changing NSCLC Treatment Landscape
Recent Videos
Related Content
Managing HER2+ Early Breast Cancer: Insights and Future Horizons
November 28th 2023Article
Sandra M. Swain, MD, FACP, FASCO, discusses the potential role for HER2-directed TKIs for the treatment of patients with early-stage HER2+ breast cancer and shares insights about emerging data that could impact the future treatment landscape.
Read More
